Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide + ADT vs enzalutamide + ADT in low-volume mHSPC
CTR20254578Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezvilutamide in prostate adenocarcinoma, sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
rezvilutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20254578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254578.